🇺🇸 FDA
Patent

US 12398212

Methods for treating or preventing asthma by administering an IL-4R antagonist

granted A61KA61K2039/505A61K2039/525

Quick answer

US patent 12398212 (Methods for treating or preventing asthma by administering an IL-4R antagonist) held by REGENERON PHARMACEUTICALS, INC. expires Mon Aug 21 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Aug 26 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 21 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
23
CPC classes
A61K, A61K2039/505, A61K2039/525, A61K2039/545, A61K39/12